[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592846":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":27,"locations":32,"responsibleParty":48,"collaborators":11,"id":50,"slug":11,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":51,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":11,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":11,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Sixth Affiliated Hospital, Sun Yat-sen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention group patients will receive anticoagulation management via MTM model","EXPERIMENTAL",null,[13],"Behavioral: Medication Therapy Management (MTM) model",{"label":15,"type":16,"description":11,"interventionNames":11},"Control group patients will be managed using a standard care.","NO_INTERVENTION",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"BEHAVIORAL","Medication Therapy Management (MTM) model","MTM model comprising five core elements: Medication Therapy Review (MTR), Personal Medication Record (PMR), Medication-Related Action Plan (MAP), interventions \\& referrals, and documentation \\& follow-up",[9],[24],{"name":25,"affiliation":5,"role":26},"xiaoyan li","PRINCIPAL_INVESTIGATOR",[28],{"name":25,"role":29,"phone":30,"phoneExt":11,"email":31},"CONTACT","13609066172","lixyan5@mail.sysu.edu.cn",[33],{"facility":5,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Guangzhou","Guangdong","5106555","China",{"type":40,"coordinates":41},"Point",[42,43],113.25,23.11667,{"lat":43,"lon":42},[46],{"name":47,"role":29,"phone":30,"phoneExt":11,"email":31},"xiaoyan li, Study Principal Invertigator",{"type":49,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100592846",false,"NCT06998745","The Impact of MTM Model on the Efficacy and Safety of Anticoagulant Therapy in Postoperative Colorectal Cancer Patients","Inclusion Criteria:\n\n1. Patients with histologically confirmed CRC and symptomatic or incidental VTE who received anticoagulant treatment.\n2. CRC patients with VTE treated with an anticoagulant for at least 3 moths.\n\nExclusion Criteria:\n\n1.Participation in this study required active anticoagulant treatment. Apart from this, there were no specific exclusion criteria.","ALL","18 Years","100 Years",{"count":59,"type":60},327,"ESTIMATED","INTERVENTIONAL",[63],"NA","Anticoagulants are classified as high-risk medications, with their main adverse drug events (ADEs) being recurrent venous thromboembolism (VTE) and bleeding events.Postoperative colorectal cancer (CRC) patients exhibit a high probability of recurrent VTE and bleeding during anticoagulation therapy.The Medication Therapy Management (MTM) model will contribute to reducing ADEs associated with anticoagulants in CRC patients.",[66],"Thrombosis, Venous","2025-05-22",{"date":69,"type":70},"2025-05-31","ACTUAL",{"date":72,"type":70},"2025-05-01",{"date":74,"type":60},"2027-12-30",{"name":5,"class":6},1]